Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5. (Q34940940)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5. |
scientific article |
Statements
Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5 (English)
Ursula Schmidt-Erfurth
Neil M Bressler
Susan B Bressler
Jordi M Monés
Mark S Blumenkranz
Guy Donati
Gary Edd Fish
Laurie A Haynes
Hilel Lewis
Michael J Potter
Constantin Pournaras
Al Reaves
Philip J Rosenfeld
Andrew P Schachat
Michel Sickenburg
Lawrence J Singerman
Jason S Slakter
Andrew Strong
Stéphane Vannier
Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group